The University of Southampton
University of Southampton Institutional Repository

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
advanced breast cancer, anthracyclines, cardiac monitoring, cardiotoxicity, liposomal anthracyclines, risk factors
0923-7534
816-827
Barrett-Lee, P J
f0104751-918b-484d-8414-db2cfa8b7d2d
Dixon, J M
103b1886-f6f7-4338-a547-ada3b76302cb
Farrell, C
46af8fd2-61ae-4be0-8b68-67aff783fab1
Jones, A
2082146f-5619-4bf8-87a0-31511c946680
Leonard, R
a85d9f7f-4d1d-439d-a237-d850eba9a748
Murray, N
f23da0c8-302a-4b4a-9dd1-f80f35979a50
Palmieri, C
42e792f2-a7ce-4461-acb2-b802bb9c012e
Plummer, C J
64ba6ff1-8b85-4330-bdc9-30aad4a3a52b
Stanley, A
d4a03380-954a-4df3-8eb9-aa7120e7b2da
Verrill, M W
e2fc0cfd-9ce9-4a56-8bec-172cd7affe73
Barrett-Lee, P J
f0104751-918b-484d-8414-db2cfa8b7d2d
Dixon, J M
103b1886-f6f7-4338-a547-ada3b76302cb
Farrell, C
46af8fd2-61ae-4be0-8b68-67aff783fab1
Jones, A
2082146f-5619-4bf8-87a0-31511c946680
Leonard, R
a85d9f7f-4d1d-439d-a237-d850eba9a748
Murray, N
f23da0c8-302a-4b4a-9dd1-f80f35979a50
Palmieri, C
42e792f2-a7ce-4461-acb2-b802bb9c012e
Plummer, C J
64ba6ff1-8b85-4330-bdc9-30aad4a3a52b
Stanley, A
d4a03380-954a-4df3-8eb9-aa7120e7b2da
Verrill, M W
e2fc0cfd-9ce9-4a56-8bec-172cd7affe73

Barrett-Lee, P J, Dixon, J M, Farrell, C, Jones, A, Leonard, R, Murray, N, Palmieri, C, Plummer, C J, Stanley, A and Verrill, M W (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology, 20, 816-827.

Record type: Article

Abstract

Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.

Full text not available from this repository.

More information

Published date: 2009
Keywords: advanced breast cancer, anthracyclines, cardiac monitoring, cardiotoxicity, liposomal anthracyclines, risk factors
Organisations: Cancer Sciences, Medicine

Identifiers

Local EPrints ID: 79468
URI: https://eprints.soton.ac.uk/id/eprint/79468
ISSN: 0923-7534
PURE UUID: 198f3200-e9bb-4c3c-bcaa-6ba7ac93bb02

Catalogue record

Date deposited: 16 Mar 2010
Last modified: 16 Oct 2017 23:58

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×